Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration.
about
Passive stiffness of rat skeletal muscle undernourished during fetal developmentOptimizing IGF-I for skeletal muscle therapeuticsHsp72 preserves muscle function and slows progression of severe muscular dystrophyrAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.Blastocyst injection of wild type embryonic stem cells induces global corrections in mdx mice.Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice.Increased extraocular muscle strength with direct injection of insulin-like growth factor-I.Increasing muscle strength as a treatment for strabismus: sustained release of insulin-like growth factor-1 in rabbit extraocular muscle.Myogenic growth factors can decrease extraocular muscle force generation: a potential biological approach to the treatment of strabismus.Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice.Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I).A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice.The insulin-like growth factor system: towards clinical applications.Approaching a new age in Duchenne muscular dystrophy treatment.Neurovascular proximity in the diaphragm muscle of adult miceSphingomyelinase depresses force and calcium sensitivity of the contractile apparatus in mouse diaphragm muscle fibers.Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice.Emerging drugs for Duchenne muscular dystrophyThe force-temperature relationship in healthy and dystrophic mouse diaphragm; implications for translational study design.Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyDevelopmental Biology and Regenerative Medicine: Addressing the Vexing Problem of Persistent Muscle Atrophy in the Chronically Torn Human Rotator CuffIncreased sphingosine-1-phosphate improves muscle regeneration in acutely injured mdx mice.Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice.Anabolic agents for improving muscle regeneration and function after injury.Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.Mechanical properties of respiratory musclesPolyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1.CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy.Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis.Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.High Fat Diet-Induced Skeletal Muscle Wasting Is Decreased by Mesenchymal Stem Cells Administration: Implications on Oxidative Stress, Ubiquitin Proteasome Pathway Activation, and Myonuclear Apoptosis.Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.Adipose tissue-derived stem cell secreted IGF-1 protects myoblasts from the negative effect of myostatin.Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats.Systemic delivery of human mesenchymal stromal cells combined with IGF-1 enhances muscle functional recovery in LAMA2 dy/2j dystrophic mice.Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice.Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury.ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies.
P2860
Q24599648-49AE02F9-7E11-4E93-9DD5-9B35696F345DQ26825444-A6AB0826-407A-43D3-9B86-9B7DC6D41C60Q28591442-35D0181D-C303-4256-9419-C06467372409Q30602105-ABF63332-6913-4934-BD84-1D989340526CQ33416809-5ECAF162-4F97-43C4-B28E-978A76C11F7CQ33816426-FFC9F0E1-6B67-4B6C-A5D0-CBFD14E5C4D5Q34530314-C9580EE4-C761-4DB3-8CC1-7C3A60E99565Q34555127-F5467AD9-418E-419A-AF86-0E53A7671CE3Q34575432-0FC588C5-BB23-4C58-A536-A59C7AE44C61Q34764061-74135340-F236-4217-BF01-905CC1CAF6C6Q35010965-E371B5B2-AFFD-4DCD-8A5A-72DF60E8BC9FQ35083651-94E760C1-0F80-4F8B-9A44-0846A4F36261Q35083822-32EA95BB-0808-4BC7-B1D6-7A6B394B29B8Q35819252-2F79394C-0795-4304-BC0D-F68C6C9C3028Q35888398-0BA17D66-0116-4502-9FA8-E5341C3A8E36Q35911586-F67BAC48-4AE1-4F02-A98A-919CD290215CQ35994710-77A0D398-9986-4353-BE6F-E86F6A030266Q36007403-A0E300BE-A803-49B1-A2FB-A5250906B6F8Q36363716-F13EB04C-3466-4236-85E8-1E7595615EA6Q36378166-8A8718D9-B983-4790-BE6C-B4A6F6F97347Q36841572-A8C87137-93AF-4548-BC93-26BE30F7FDBBQ36875163-6F1DA26D-CCF7-41DC-BED3-1843C2C34750Q37114072-5EA568D6-F8D2-4E05-AC61-82505769F11BQ37116446-164BFC82-F4DF-440D-9233-9B400475369CQ37171075-19F4CC1D-77BA-42E4-AF4E-CD2676F1F96CQ37257924-64ACA020-86F1-4B98-9F60-7CF47FD8CCF4Q38165141-F8D3E9A0-818C-4ED0-AF33-39BC2028B0ADQ39219980-C560E64D-A696-45E3-AD82-4C6FD6610C85Q39493006-01B93864-7E72-418C-BA82-75658A600247Q39529950-76839AFF-EA8E-4C31-9731-9AA42764076EQ39629598-31799FE5-6E3C-424E-8B86-C97C14AC4058Q41031903-A458D115-2BFC-46C4-9E24-B69B4E39E262Q41479479-129A00F1-6A41-4095-8CDD-3B95ACF6C878Q41527279-1EB50FB7-95BF-4AE6-AC05-A5727406286BQ41860481-69043624-2BBA-4FC6-B313-A59111C3A3E3Q44655921-E2B2D086-FD35-418F-8A49-05D748B21BB6Q44949025-F93AB637-7330-4A74-8A79-23CC3AA168F3Q45023070-D6431597-E240-4A0C-B9D6-EB32162EE585Q45861368-369AEAB2-290B-4765-B76F-8AB310EF4258Q45871995-8A0ECA73-0D6C-42E8-B911-B17928D95D94
P2860
Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Improved contractile function ...... rowth factor-I administration.
@ast
Improved contractile function ...... rowth factor-I administration.
@en
type
label
Improved contractile function ...... rowth factor-I administration.
@ast
Improved contractile function ...... rowth factor-I administration.
@en
prefLabel
Improved contractile function ...... rowth factor-I administration.
@ast
Improved contractile function ...... rowth factor-I administration.
@en
P2093
P2860
P1476
Improved contractile function ...... rowth factor-I administration.
@en
P2093
David R Plant
Gordon S Lynch
Kerri S Leeding
Leon A Bach
Paul Gregorevic
P2860
P304
P356
10.1016/S0002-9440(10)64502-6
P407
P577
2002-12-01T00:00:00Z